NASDAQ: CNSYCerenome Inc Stock
$2.03+0.00 (+0%)
Updated Sep 18, 2026
CNSY Price
$2.03
Fair Value Price
-$1.77
Market Cap
$15.41M
52 Week Low
$2.00
52 Week High
$23.50
P/E
-0.6x
P/B
2.82x
P/S
7.17x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.20M
Earnings
-$26.09M
Gross Margin
100%
Operating Margin
-620.18%
Profit Margin
-620.7%
Debt to Equity
1.57
Operating Cash Flow
-$22M
Beta
0.77
Next Earnings
Oct 29, 2026
Ex-Dividend
N/A
Next Dividend
N/A
CNSY Overview
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CNSY's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -12.86% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CNSY
Ranked#460 of 461
Ranked#460 of 461
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.60 | A | |
| $350.84 | A | |
| $42.02 | A |
Be the first to know about important CNSY news, forecast changes, insider trades & much more!
CNSY News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CNSY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CNSY ($2.03) is overvalued by 214.84% relative to our estimate of its Fair Value price of -$1.77 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CNSY ($2.03) is not significantly undervalued (214.84%) relative to our estimate of its Fair Value price of -$1.77 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CNSY is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CNSY due diligence checks available for Premium users.
Valuation
CNSY fair value
Fair Value of CNSY stock based on Discounted Cash Flow (DCF)
Price
$2.03
Fair Value
-$1.77
Undervalued by
214.84%
CNSY ($2.03) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CNSY ($2.03) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CNSY is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CNSY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.6x
Industry
9.29x
Market
44.48x
CNSY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.82x
Industry
5.28x
CNSY is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CNSY's financial health
Profit margin
Revenue
$411.0k
Net Income
-$9.0M
Profit Margin
-2,191.2%
CNSY's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CNSY's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$14.0M
Liabilities
$8.6M
Debt to equity
1.57
CNSY's short-term assets ($11.77M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CNSY's short-term assets ($11.77M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CNSY's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CNSY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.1M
Investing
$5.4M
Financing
$1.1M
CNSY's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CNSY vs Biotech Stocks
Cerenome Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.